Shanghai BAODIE

Baodie Pharmaceutical is a Shanghai-based biotechnology company specializing in the discovery and development of small molecule therapeutics targeting challenging protein-protein interactions (PPIs). The company leverages a proprietary drug discovery platform to address "undruggable" targets in oncology and other serious diseases. Its lead programs focus on the RAS signaling pathway, including specific inhibitors for KRAS mutations such as G12D. Baodie aims to provide next-generation precision medicines for patients with limited treatment options in indications like pancreatic and colorectal cancer. The firm is supported by leading venture capital investors including Decheng Capital and Matrix Partners China.